Unavailable
Unavailable
Save time and jump to the most important pieces.
DEFA14A - Scienture Holdings, Inc. (0001382574) (Filer)
EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)
S-1/A - Scienture Holdings, Inc. (0001382574) (Filer)
TAMPA, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a Specialty Pharma company with a novel pipeline of brand products, is pleased to announce the participation of Narasimhan Mani, Ph.D., MBA (President of Scienture, LLC) as an invited speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) India, one of the premiere conferences organized in India specifically in the area of drug discovery and development. The conference will take place January 23-25, 2025, at BITS Pilani, Hyderabad Campus in Hyderabad, India. Dr. Mani will deliver a presentation on the specialty pharmaceutical industry with a specific focus on t
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the "Company") (NASDAQ:SCNX), a specialty pharma company with a novel pipeline of brand products, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The Company's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the Company's recent developments, growth strategy, and investment opportunities. About The Microcap Conference 2025 The Micr
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC ("the "Company"), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), focused on developing and commercializing novel branded, specialty pharma products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No. 12,156,869 (the ‘869 patent), further strengthening the intellectual property position and coverage for the Company's SCN-102 product. The ‘869 patent is in addition to the previously granted patent for SCN-102 by the USPTO, No. 11,890,273 (the ‘273 patent). The ‘869 patent and the ‘273 patent, both titled, "LOSARTAN LIQUID FORMULATIONS AND METHODS OF U